These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9053487)

  • 21. Treatments for newly diagnosed advanced ovarian cancer: analysis of survival data and cost-effectiveness evaluation.
    Messori A; Trippoli S; Becagli P; Tendi E
    Anticancer Drugs; 1998 Jul; 9(6):491-502. PubMed ID: 9877236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NICE approves Taxol for ovarian cancer.
    Kmietowicz Z
    BMJ; 2000 May; 320(7245):1293. PubMed ID: 10807610
    [No Abstract]   [Full Text] [Related]  

  • 23. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.
    Leighl NB; Shepherd FA; Kwong R; Burkes RL; Feld R; Goodwin PJ
    J Clin Oncol; 2002 Mar; 20(5):1344-52. PubMed ID: 11870178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer.
    Foote J; Secord AA; Liang M; Cohn DE; Jewell E; Havrilesky LJ
    J Oncol Pract; 2017 Dec; 13(12):e1030-e1039. PubMed ID: 29016225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparative pharmaco-economic analysis of docetaxel with cisplatin and cyclophosphamide with cisplatin in first-line chemotherapy of advanced ovarian cancer].
    Gorbunova VA; Khokhlova SV; Komarova BP; Orel NF; Besova NS
    Vopr Onkol; 2002; 48(6):695-9. PubMed ID: 12530266
    [No Abstract]   [Full Text] [Related]  

  • 28. An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer.
    Dalton HJ; Yu X; Hu L; Kapp DS; Benjamin I; Monk BJ; Chan JK
    Gynecol Oncol; 2012 Feb; 124(2):199-204. PubMed ID: 22055763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
    Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
    J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
    Havrilesky LJ; Pokrzywinski R; Revicki D; Higgins RV; Nycum LR; Kohler MF; Berchuck A; Myers ER; Secord AA
    Cancer; 2012 Jan; 118(2):386-91. PubMed ID: 21598242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.
    Evans WK
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resource implications of palliative chemotherapy for ovarian cancer.
    Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
    J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer.
    Earle CC; Evans WK
    Cancer Prev Control; 1997 Oct; 1(4):282-8. PubMed ID: 9765752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience.
    Thigpen T; Vance RB; McGuire WP; Hoskins WJ; Brady M
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):23-31. PubMed ID: 8553080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.
    Alba E; Ciruelos E; López R; López-Vega JM; Lluch A; Martín M; Muñoz M; Sánchez-Rovira P; Seguí MÁ; Liria MR; Pérez-Alcántara F
    Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):381-91. PubMed ID: 23534988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
    Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
    J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.